AbbVie gains EU approval of atogepant for acute migraine
Source: SeekingAlpha
2026-06-02 06:54:53 ET
More on AbbVie
- AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript
- AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- AbbVie's Growth Engine Is Firing On All Cylinders
- AbbVie gains approval of Decnupaz for rare hematologic malignancy
- Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation
Read the full article on Seeking Alpha
For further details see:
AbbVie gains EU approval of atogepant for acute migraine
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
2.61% G/L:
$229.18 Last:
2,858,492 Volume:
$227.37 Open:
ABBV Latest News
June 02, 2026 02:50:00 pm
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
June 02, 2026 10:05:00 am
The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains
June 02, 2026 08:00:00 am
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
